Alnylam Pharmaceuticals (ALNY) : $15.38 million worth of transactions were on upticks in Alnylam Pharmaceuticals (ALNY), compared to $6.84 million on downticks. The ratio between the two was 2.25, whereas, the net money flow stood at a healthy $8.54 million on Tuesdays session. The consistent buying on upticks in the stock accounted for $8.37million worth of trades. The total money flow into the stock stood at $8.37 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -1.13%. The stock was trading at $70.75, with a drop of $0.81 over the previous days close. The stock recorded -0.07% for the week.
Also, Brokerage firm Jefferies maintains its rating on Alnylam Pharmaceuticals (NASDAQ:ALNY). As per the latest information, the brokerage house raises the price target to $86 per share from a prior target of $80. The shares have been rated Buy. The rating by the firm was issued on August 5, 2016.
Alnylam Pharmaceuticals, Inc. has lost 6.65% in the last five trading days and dropped 1.46% in the last 4 weeks. Alnylam Pharmaceuticals, Inc. is up 0.3% in the last 3-month period. Year-to-Date the stock performance stands at -24.85%.
Alnylam Pharmaceuticals (NASDAQ:ALNY): The stock opened at $71.32 on Tuesday but the bulls could not build on the opening and the stock topped out at $73.28 for the day. The stock traded down to $70.28 during the day, due to lack of any buying support eventually closed down at $70.75 with a loss of -1.13% for the day. The stock had closed at $71.56 on the previous day. The total traded volume was 512,896 shares.
In a related news,The director officer (CEO) of Alnylam Pharmaceuticals, Inc., Maraganore John sold 30,151 shares at $64.83 on July 19, 2016. The Insider selling transaction had a total value worth of $1,954,689. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.